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Abstract
Background: GPI anchor attachment is catalyzed by the GPI transamidase (GPIT) complex. GAA1,
PIG-T and PIG-U are the three of five GPIT subunits. Previous studies demonstrated amplification
and overexpression of GPIT subunits in bladder and breast cancer with oncogenic function. We
performed an analysis of these subunits in head and neck squamous cell carcinoma (HNSCC).
Results: To evaluate GAA1, PIG-T and PIG-U in HNSCC, we used quantitative PCR (QPCR) and
quantitative RT-PCR (QRT-PCR) to determine the copy number of those genes in primary tumors
and the matching lymphocytes in 28 patients with HNSCC and quantified RNA expression of those
genes in 16 primary HNSCC patients and 4 normal control tissue samples. GAA1  showed a
significant increase in normalized mRNA expression, 2.11 (95% CI: 1.43, 2.79), in comparison to
that of normal controls, 0.43 (95% CI: -0.76, 1.61), p = 0.014 (Mann-Whitney test). The mean
genomic copy number of GAA1 was significantly increased in HNSCC, 0.59 (95% CI: 0.50, 0.79), in
comparison to lymphocyte DNA, 0.35 (95% CI: 0.30, 0.50), p = 0.001 (paired t-test).
Conclusion: An increased expression level and elevated copy number for GAA1 suggest a role for
this GPI anchor subunit in HNSCC.
Background
HNSCC has an annual incidence of over than 40,000
cases per year in United States and is characterized by
local tumor aggressiveness, a high rate of early recur-
rences, and development of second primary carcinomas
[1]. Despite modern therapeutic strategies, overall 5-year
survival rate does have only modestly improved.
Glycosylphosphatidylinositol (GPI) anchoring is a mem-
brane attachment mechanism for cell surface proteins
widely used in eukaryotes. GPI anchor attachment is cata-
Published: 21 November 2007
Molecular Cancer 2007, 6:74 doi:10.1186/1476-4598-6-74
Received: 31 July 2007
Accepted: 21 November 2007
This article is available from: http://www.molecular-cancer.com/content/6/1/74
© 2007 Jiang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2007, 6:74 http://www.molecular-cancer.com/content/6/1/74
Page 2 of 7
(page number not for citation purposes)
lyzed by GPI transamidase (GPIT) complex, which is com-
posed of at least five subunits: Phosphatidylinositol Glycan
Class U (PIG-U), Glycosylphosphatidylinositol Anchor Attach-
ment Protein 1 (GAA1), Phosphatidylinositol Glycan Class K
(Gpi8), Phosphatidylinositol Glycan Class S (PIG-S), Phos-
phatidylinositol Glycan Class T (PIG-T) [2-11]. All of the
subunits are required for GPIT to function [3,6-8]. Gpi8 is
the likely enzymatic component of the GPIT complex and
can be cross-linked to proproteins [5,8,12-14]. GAA1 is
able to assemble into PIG-U-containing GPIT complexes
that are capable of interacting with a proprotein substrate,
and this subunit also is critical in GPI recognition by GPIT
[15]. PIG-U contains a sequence motif found in yeast and
mammalian fatty acid elongases. This motif has been sug-
gested to play a role in recognizing long chain fatty acids
in GPI [3], and PIG-T  contains endoplasmic reticulum
(ER) localization information.
In a previous study amplification of PIG-U was noted in
the bladder cancer, and was found to contribute to an
oncogenic phenotype [16]. A recent study showed PIG-T
and GPAA1 were overexpressed in breast cancer cell lines
and primary tumors and caused malignant transforma-
tion in vitro [17]. Genomic amplification and/or DNA
copy number gain are common genetic alterations in can-
cer that lead to the overexpression of oncogenes [18-20].
PIG-U  and PIG-T  are located at chromosome 20q and
GAA1 is located at chromosome 8q, a chromosomal arm
with increased copy number in HNSCC [21,22]. To eval-
uate PIG-U, PIG-T and GAA1 as possible oncogene candi-
dates in HNSCC, we employed real-time PCR and real-
time RT-PCR to determine copy number and RNA expres-
sion of those genes in primary HNSCCs.
Results and discussion
Analysis of mRNA expression of GAA1, PIG-T and PIG-U 
by QRT-PCR
Overexpression of PIG-U, one of the GPIT subunits, was
reported previously in primary bladder cancer and cell
lines [16]. By comparing the mRNA expression ratios of
the oral mucosa of normal subjects and tumor tissues of
HNSCC patients, we were able to assess GAA1, PIG-T and
PIG-U expression alteration in a quantitative manner. In
this study, 68.75%, 31.25% and 43.75% of HNSCC
exhibited higher mRNA expression in comparison to nor-
mal controls for GAA1, PIG-T and PIG-U, respectively (Fig
1). In particular, GAA1 showed a significant increase in
mRNA expression in HNSCC, 2.11 (95% CI: 1.43, 2.79),
in comparison to that in normal controls, 0.43 (95% CI: -
0.76, 1.61), p = 0.014 (Mann-Whitney test).
Analysis of copy number of GAA1, PIG-T and PIG-U by 
QPCR
The combination of QPCR and QRT-PCR is a facile
approach to detecting gene amplification and over-expres-
mRNA Expression Ratio of GAA1, PIGT and PIGU vs β-Actin Figure 1
mRNA Expression Ratio of GAA1, PIGT and PIGU vs β-Actin. 
The expression differential of GAA1, PIGT and PIGU between 
normal (health subjects mucosa) and HNSCC was measured 
by calculating relative fluorescence amplification of tran-
scripts of gene of interests normalized by the corresponding 
β-Actin signal. N, normal; T, HNSCC.

	


vs ȕ











ȕ








 





 !"

#

$
$
$

#
	


%&vs ȕ






%
&



ȕ








'#!"
 
$

#
'
(
!
	


%&)vs ȕ






%
&

)

ȕ








(' !"
 
	


vs ȕ











ȕ








 





 !"

#

$
$
$

#
	


%&vs ȕ






%
&



ȕ








'#!"
 
$

#
'
(
!
	


%&)vs ȕ






%
&

)

ȕ








(' !"
 Molecular Cancer 2007, 6:74 http://www.molecular-cancer.com/content/6/1/74
Page 3 of 7
(page number not for citation purposes)
sion in tumor specimens. To assess whether the copy
number of GAA1, PIG-T and  PIG-U  was altered in
HNSCC, we performed QPCR in 28 HNSCC and matched
peripheral leukocyte DNA. The relative copy number of
each gene vs β-Actin is shown in Table 1. Overall, a trend
of increasing copy number was found in HNSCC. GAA1
copy number was significantly increased in primary
HNSCCs, 0.59 (95% CI: 0.50, 0.79), in comparison to
peripheral leukocyte DNA, 0.35 (95% CI: 0.30, 0.50), p =
0.001, while PIG-U  showed a border line difference
(paired t-test). (Fig 2) Taken together, the increased mRNA
expression of GAA1 and low level copy number increase
in HNSCC may be relevant as a possible contributor to
oncogenic transformation in HNSCC.
Many membranous enzymes, receptors, differentiation
antigens and other biologically active proteins proved to
be bound to the plasma membrane by GPI. Recent studies
report that there are increased levels of the GPI-anchored
adhesion molecules CEACAM5, CEACAM6 and mesothe-
lin in response to forced expression of ΔN-TCF-1B, which
could contribute to the induction of effecter molecules
potentially relevant for tumor invasion in colorectal carci-
nomas patients [23]. Notably, our data showed that GAA1
copy numbers were much higher in HNSCC than in con-
trol white blood cells. This difference was highly signifi-
cant, which was corresponded to the elevated RNA
expression level in HNSCC patients.
Clinical associations with copy number alterations in 
GAA1, PIG-T and PIG-U
To analyze whether clinical factors are associated with
GAA1, PIG-T and PIG-U as potential markers, therefore,
we further sub-grouped HNSCC patients by gender, race,
stage and tumor site. We found that female HNSCC
patients had a higher copy number of GAA1, 0.77 (95%
CI: 0.63, 0.91), in comparison to male patients 0.58 (95%
CI: 0.40, 0.75), p = 0.025 (Mann-Whitney test) (Table 2).
In comparison to GAA1, PIG-T showed significant differ-
ence of copy number in paired lymphocytes DNA
between male and female patients but not in tumor tissue
DNA (Table 3b). Neither race nor tumor site was inde-
pendently associated with GAA1 (Table 2), PIG-T (Table
3) and PIG-U  (Table 4) copy number alterations. One
might, therefore, speculate that gender might be a factor
in the catalysis of GPI anchor attachment. Five out of 28
HNSCCs were located in larynx. We noticed that the PIG-
T DNA copy number of laryngeal HNSCC, showed a rela-
tively lower value in comparison to that in the other sites
(Table 3), however, we were unable to draw definite con-
clusions due to limited case numbers. Additionally, no
significances were shown among different stages for each
gene.
Conclusion
Our data indicate that increasing of copy number and
mRNA expression of GAA1 is characteristic for HNSCC
and  GAA1  play a role for this GPI anchor subunit in
HNSCC.
Methods
Subjects
Genomic DNA samples from 28 HNSCC tissues and
matching lymphocytes were subjected to QPCR analysis.
RNA of tissue samples from 16 microdissected HNSCCs
and 4 oral mucosal biopsies of healthy people were sub-
jected to QRT-PCR. All samples were collected at the
Department of Otolaryngology-Head and Neck Surgery,
School of Medicine, The Johns Hopkins University, after
appropriate approval was obtained from the Johns Hop-
kins institutional review board (IRB approval # 03-04-11-
131d).
Cell lines and culture conditions
DNA and RNA from a virally transformed human cutane-
ous keratinocyte cell line (HaCaT) were used as standards
for QPCR and QRT-PCR. The HaCaT cell line was grown
in DMEM media supplemented with 10% FBS and 1%
Penicillin-Streptomycin. Media components were
obtained from Gibco Invitrogen Corporation (Carlsbad,
CA) and cells were incubated at 37°C in an atmosphere of
5% CO2/95% relative humidity.
Quantitative PCR
A Perkin-Elmer/ABI 7900 thermocycler (Applied Biosys-
tems, CA) was used to perform QPCR amplification for β-
actin, PIG-U, PIG-T and Gaa1. β-actin primer and probe
sequences used previously were employed in this study
[24].  PIG-U[16],  PIG-T  and  GAA1  primer and probe
sequences were listed in Table 5. Primers were custom
Table 1: Copy number alteration of GAA1, PIG-T and PIG-U in HNSCC
DNA Copy Number Ratio Number Mean Median 95%CI p (paired-t test)
Log (GAA1/β-Actin) Control 28 0.40 0.35 (0.30, 0.50) 0.001
HNSCC 28 0.63 0.59 (0.50, 0.76)
Log (PIG-T/β-Actin) Control 28 0.34 0.28 (0.24, 0.45) 0.365
HNSCC 28 0.40 0.43 (0.30, 0.50)
Log (PIG-U/β-Actin) Control 28 0.59 0.45 (0.46, 0.72) 0.058
HNSCC 28 0.74 0.64 (0.61, 0.87)Molecular Cancer 2007, 6:74 http://www.molecular-cancer.com/content/6/1/74
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made and obtained from Invitrogen (Carlsbad, CA). All
TaqMan probes (Applied Biosystems, Foster City, CA)
were 5'-FAM and 3'-TAMRA labeled. PCR amplifications
were carried out in buffer containing: 16.6 mM ammo-
nium sulfate, 67 mM Trizma (pH 8.8), 2.5 mM MgCl2, 10
mM β-mercaptoethanol, 0.1% DMSO, 600 nM each of
forward and reverse primers, 200 nM TaqMan probe, 0.6
units Platinum Taq polymerase, and 2% ROX reference
dye. 500 picograms of DNA were used to amplify the
mitochondrial regions whereas 10 ng were used to
amplify  β-actin. The real-time PCR reactions were per-
formed in triplicate for each gene. Data analysis was per-
formed using Microsoft Excel software.PIG-U, PIG-T and
GAA1 were normalized using the corresponding β-actin
signal.
Statistical analysis
The major statistical first endpoint in this study was the
comparison of the difference in PIG-U, PIG-T and GAA1
quantitative DNA ratio between lymphocytes DNA and
tumor tissue DNA in the HNSCC patients. The second
endpoint in this study was PIG-U, PIG-T and GAA1 RNA
expression differences between HNSCC patients and nor-
mal control subjects. Distributions of PIG-U, PIG-T and
GAA1 DNA and RNA quantitative ratios were examined
graphically using scatter plots and bar plots with logarith-
mic scales. Log transformation was chosen for these val-
ues and the difference taken for statistical analyses. Paired
t-tests were used to determine if these changes were signif-
icantly different from each other. All statistical computa-
tions were performed using the SPSS system (SPSS,
Chicago) and all p values reported are two-sided.
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Relative DNA copy number of GAA1, PIGT and PIGU in  HNSCC Figure 2
Relative DNA copy number of GAA1, PIGT and PIGU in 
HNSCC. The copy number differential of GAA1, PIGT and 
PIGU between paired lymphocytes and HNSCC was meas-
ured by calculating relative fluorescence amplification of gene 
of interest normalized by the corresponding β-Actin signal 
using standard curve method. N, normal; T, HNSCC.
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Table 3: The effects of clinical parameters on copy number of PIG-T
Log (PIG-T/β-Actin) Number Mean Median 95%CI p (Mann-Whitney test)
Control Male 20 0.28 0.25 (0.15, 0.41) 0.042*
Female 8 0.51 0.56 (0.30, 0.72)
HNSCC Male 20 0.37 0.39 (0.24, 0.49) 0.222
Female 8 0.48 0.54 (0.25, 0.71)
Control White 17 0.33 0.44 (0.18, 0.47) 0.621
Other 11 0.37 0.26 (0.18, 0.57)
HNSCC White 17 0.40 0.45 (0.29, 0.51) 0.621
Other 11 0.40 0.41 (0.16, 0.63)
Control OC 11 0.39 0.43 (0.18, 0.61)
HP 3 0.46 0.54 (-0.40, 1.33) 0.938
L 5 0.35 0.25 (-0.01, 0.72) 0.692
OP 9 0.24 0.24 (0.08, 0.40) 0.239
HNSCC OC 11 0.52 0.52 (0.34, 0.70)
HP 3 0.44 0.10 (-0.34, 1.22) 0.586
L 5 0.20 0.19 (-0.08, 0.48) 0.027*
OP 9 0.35 0.41 (0.17, 0.53) 0.271
Table 2: The effects of clinical parameters on copy number of GAA1
Log (Gaa1/β-Actin) Number Mean Median 95%CI p (Mann-Whitney test)
Control Male 20 0.36 0.33 (0.25, 0.48) 0.242
Female 8 0.49 0.39 (0.29, 0.70)
HNSCC Male 20 0.58 0.44 (0.40, 0.75) 0.025*
Female 8 0.77 0.75 (0.63, 0.91)
Control White 17 0.35 0.32 (0.23, 0.46) 0.165
Other 11 0.48 0.43 (0.29, 0.68)
HNSCC White 17 0.52 0.48 (0.42, 0.63) 0.095
Other 11 0.81 0.68 (0.52, 1.09)
Control OC 11 0.35 0.33 (0.18, 0.53)
HP 3 0.46 0.43 (0.05, 0.88) 0.392
L 5 0.42 0.28 (0.04, 0.80) 0.865
OP 9 0.43 0.38 (0.22, 0.64) 0.518
HNSCC OC 11 0.67 0.68 (0.39, 0.94)
HP 3 0.55 0.11 (-0.26, 1.37) 0.697
L 5 0.65 0.61 (0.37, 0.92) 0.955
OP 9 0.61 0.57 (0.36, 0.86) 0.676Molecular Cancer 2007, 6:74 http://www.molecular-cancer.com/content/6/1/74
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